Wednesday, Nov 05, 2003
Front Page |
Southern States |
Other States |
Advts: Classifieds | Employment | Obituary |
By Our Staff Correspondent
After a contractual relationship of ten years with Nicholas Piramal (NPIL), FHLR decided to end the Frame Cooperation Agreement this month. This means that NPIL would not have any access to new Roche Pharma products for distribution.
FHLR plans to invest over 10 million Swiss Francs in India in the next fiscal year. It has also announced a reduction in prices of its existing therapies.
Also, for the first time, Roche is looking at introducing therapies in the areas of dermatology and osteoporosis in India. Therapies like anti-CMV and treatment of bone metastasis are in the pipeline for India in the coming year. The company will be launching CRC (colorectal and renal cancer) drugs. Roche is also introducing the EAP in India where a molecule tried internationally is available for treating Indian patients much before the International approval.
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |
Copyright © 2003, The
Hindu. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of